“ The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint”
The Efti/Keytruda combo ,approximately 8x the Keytruda mono results in head and neck cancer.With 5 complete responses in a extremely difficult to treat indication,with limited options.
Tumour shrinkage is considered to be a surrogate end point.
Overnight Market report, page-1488
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |